Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L

Lack of absolute selectivity against cancer cells is a major limitation for current cancer therapies. In the previous study, we developed a prodrug strategy for selective cancer therapy using a masked cytotoxic agent puromycin [Boc-Lys(Ac)-Puromycin], which can be sequentially activated by histone d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueki, Nobuhide, Wang, Wei, Swenson, Cooper, McNaughton, Caroline, Sampson, Nicole S., Hayman, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860889/
https://www.ncbi.nlm.nih.gov/pubmed/27162551
http://dx.doi.org/10.7150/thno.13826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860889/
https://www.ncbi.nlm.nih.gov/pubmed/27162551
http://dx.doi.org/10.7150/thno.13826

Ejemplares similares